SCHEDULE: Sirenia Capital Management Discloses 6.1% Stake in Immunome Inc.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 6.1% of Immunome Inc.'s common stock as of March 31, 2026.

Summary

• Sirenia Capital Management LP and Alex Silverstein have jointly reported beneficial ownership of 6,895,000 shares of Immunome Inc. common stock.
• This represents 6.1% of the total outstanding shares as of February 27, 2026.
• The filing is made under Schedule 13G, indicating the ownership is not for the purpose of changing or influencing control of the issuer.
• Sirenia Capital Management LP is identified as an investment adviser, and Alex Silverstein is identified as a holder of a controlling interest in the general partner of Sirenia Capital Management LP.
• Both parties have entered into a joint filing agreement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, indicating significant investor confidence, but lacking specific operational or financial performance data to warrant a higher score.

Positives

• Significant stake acquired by Sirenia Capital Management LP and Alex Silverstein, indicating confidence in Immunome Inc.'s prospects.
• The filing is made under Schedule 13G, suggesting a passive investment approach rather than a hostile takeover attempt.

Risks

• The filing does not detail specific risks associated with Immunome Inc.'s business operations or the investment itself.
• Potential for future changes in ownership or investment strategy by Sirenia Capital Management LP and Alex Silverstein.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Immunome Inc. It only reports the current ownership stake.

Industry Context

StockSavvy.ai notes that significant stake acquisitions reported via Schedule 13G filings often signal increased institutional interest or a belief in the target company's growth potential within the biotechnology sector.

Stakeholder Impact

• Shareholders may view the increased institutional ownership positively, potentially leading to greater scrutiny and support for the company's strategy.
• The market may interpret this as a sign of confidence in Immunome Inc.'s long-term prospects.

Next Steps

• Monitor future filings from Sirenia Capital Management LP and Alex Silverstein for any changes in their ownership stake.
• Observe Immunome Inc.'s performance and strategic developments that may have influenced this investment.

Key Dates

Recommendation

Based solely on this Schedule 13G filing, which reports a significant passive ownership stake, a 'hold' recommendation is appropriate. The filing indicates investor confidence but does not provide sufficient operational or financial details to warrant a buy or sell decision. Further analysis of Immunome Inc.'s business performance and future prospects is required.

Keywords

Immunome Inc., Schedule 13G, Sirenia Capital Management LP, Alex Silverstein, Beneficial Ownership, SEC Filing, Investment Adviser, Common Stock